The NIH’s Advanced Research Projects Agency for Health (ARPA-H) awarded Satio the $3.5 million in September 2023. This contract aimed to help the company develop SatioRx, its intradermal drug delivery device. The compact, inexpensive device features disposable microneedle components for precise delivery. It remotely enables the delivery of a precise, metered dose of any liquid drug approved for transdermal delivery.

Satio designed the device to provide stable, controlled delivery through the hollow microneedle (HMN) array. The approach combines a reusable motor-driven applicator with a low-cost disposable. This disposable houses a standard drug cartridge, an adhesive patch, microneedles and a Go/No-go pressure sensor and NFC antenna. It accepts a range of sizes between 1 mL and 5 mL.